Takeda Pharmaceutical (TKPHF) EBT Margin (2017 - 2025)
Historic EBT Margin for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to 11.23%.
- Takeda Pharmaceutical's EBT Margin fell 36200.0% to 11.23% in Q4 2025 from the same period last year, while for Dec 2025 it was 23.76%, marking a year-over-year increase of 69700.0%. This contributed to the annual value of 3.82% for FY2025, which is 25800.0% up from last year.
- As of Q4 2025, Takeda Pharmaceutical's EBT Margin stood at 11.23%, which was down 36200.0% from 25.55% recorded in Q3 2025.
- In the past 5 years, Takeda Pharmaceutical's EBT Margin registered a high of 29.19% during Q1 2025, and its lowest value of 4.52% during Q1 2024.
- Its 5-year average for EBT Margin is 16.15%, with a median of 15.42% in 2022.
- Its EBT Margin has fluctuated over the past 5 years, first plummeted by -192100bps in 2024, then surged by 337100bps in 2025.
- Over the past 5 years, Takeda Pharmaceutical's EBT Margin (Quarter) stood at 8.01% in 2021, then rose by 22bps to 9.77% in 2022, then soared by 104bps to 19.97% in 2023, then fell by -26bps to 14.85% in 2024, then decreased by -24bps to 11.23% in 2025.
- Its EBT Margin stands at 11.23% for Q4 2025, versus 25.55% for Q3 2025 and 25.14% for Q2 2025.